Literature DB >> 22284361

Discovery of potent and selective covalent inhibitors of JNK.

Tinghu Zhang1, Francisco Inesta-Vaquera, Mario Niepel, Jianming Zhang, Scott B Ficarro, Thomas Machleidt, Ting Xie, Jarrod A Marto, NamDoo Kim, Taebo Sim, John D Laughlin, Hajeung Park, Philip V LoGrasso, Matt Patricelli, Tyzoon K Nomanbhoy, Peter K Sorger, Dario R Alessi, Nathanael S Gray.   

Abstract

The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response. Here, we report the discovery of irreversible inhibitors of JNK1/2/3. We describe two JNK3 cocrystal structures at 2.60 and 2.97 Å resolution that show the compounds form covalent bonds with a conserved cysteine residue. JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue. Extensive biochemical, cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compound will be broadly useful as a pharmacological probe of JNK-dependent signal transduction. Potential lead compounds have also been identified for kinases, including IRAK1, PIK3C3, PIP4K2C, and PIP5K3.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22284361      PMCID: PMC3270411          DOI: 10.1016/j.chembiol.2011.11.010

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  62 in total

1.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

2.  DataPflex: a MATLAB-based tool for the manipulation and visualization of multidimensional datasets.

Authors:  Bart S Hendriks; Christopher W Espelin
Journal:  Bioinformatics       Date:  2009-12-04       Impact factor: 6.937

3.  A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra.

Authors:  Z Zhang; A G Marshall
Journal:  J Am Soc Mass Spectrom       Date:  1998-03       Impact factor: 3.109

4.  MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Authors:  Hiroshi Hirai; Hiroshi Sootome; Yoko Nakatsuru; Katsuyoshi Miyama; Shunsuke Taguchi; Kyoko Tsujioka; Yoko Ueno; Harold Hatch; Pradip K Majumder; Bo-Sheng Pan; Hidehito Kotani
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

5.  A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.

Authors:  Shane Atwell; Jason M Adams; John Badger; Michelle D Buchanan; Ingeborg K Feil; Karen J Froning; Xia Gao; Jörg Hendle; Kevin Keegan; Barbara C Leon; Hans J Müller-Dieckmann; Vicki L Nienaber; Brian W Noland; Kai Post; K R Rajashankar; Aurora Ramos; Marijane Russell; Stephen K Burley; Sean G Buchanan
Journal:  J Biol Chem       Date:  2004-10-26       Impact factor: 5.157

6.  Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

Authors:  J B Smaill; G W Rewcastle; J A Loo; K D Greis; O H Chan; E L Reyner; E Lipka; H D Showalter; P W Vincent; W L Elliott; W A Denny
Journal:  J Med Chem       Date:  2000-04-06       Impact factor: 7.446

7.  Structural bioinformatics-based design of selective, irreversible kinase inhibitors.

Authors:  Michael S Cohen; Chao Zhang; Kevan M Shokat; Jack Taunton
Journal:  Science       Date:  2005-05-27       Impact factor: 47.728

8.  Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

Authors:  Andreas Schirmer; Jonathan Kennedy; Sumati Murli; Ralph Reid; Daniel V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

9.  Inhibitors of c-jun-N-terminal kinase (JNK).

Authors:  Philip LoGrasso; Theodore Kamenecka
Journal:  Mini Rev Med Chem       Date:  2008-07       Impact factor: 3.862

10.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

View more
  142 in total

1.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.

Authors:  Turgut Dogruluk; Yiu Huen Tsang; Maribel Espitia; Fengju Chen; Tenghui Chen; Zechen Chong; Vivek Appadurai; Armel Dogruluk; Agna Karina Eterovic; Penelope E Bonnen; Chad J Creighton; Ken Chen; Gordon B Mills; Kenneth L Scott
Journal:  Cancer Res       Date:  2015-12-01       Impact factor: 12.701

2.  E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin.

Authors:  Craig MacKay; Eilís Carroll; Adel F M Ibrahim; Amit Garg; Gareth J Inman; Ronald T Hay; Arno F Alpi
Journal:  Cancer Res       Date:  2014-03-31       Impact factor: 12.701

Review 3.  Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development.

Authors:  Juan Wang; Guixiang Tai
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

4.  Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.

Authors:  Fleur M Ferguson; Zainab M Doctor; Scott B Ficarro; Christopher M Browne; Jarrod A Marto; Jared L Johnson; Tomer M Yaron; Lewis C Cantley; Nam Doo Kim; Taebo Sim; Matthew J Berberich; Marian Kalocsay; Peter K Sorger; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

5.  A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity.

Authors:  Christof T Kaltenmeier; Laura L Vollmer; Lawrence A Vernetti; Lindsay Caprio; Keanu Davis; Vasiliy N Korotchenko; Billy W Day; Michael Tsang; Keren I Hulkower; Michael T Lotze; Andreas Vogt
Journal:  J Pharmacol Exp Ther       Date:  2017-02-02       Impact factor: 4.030

6.  Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14.

Authors:  Fleur M Ferguson; Zainab M Doctor; Scott B Ficarro; Jarrod A Marto; Nam Doo Kim; Taebo Sim; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2019-05-23       Impact factor: 2.823

7.  JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention.

Authors:  Michael P Lisanti; Aristotelis Tsirigos; Stephanos Pavlides; Kimberley Jayne Reeves; Maria Peiris-Pagès; Amy L Chadwick; Rosa Sanchez-Alvarez; Rebecca Lamb; Anthony Howell; Ubaldo E Martinez-Outschoorn; Federica Sotgia
Journal:  Cell Cycle       Date:  2013-12-05       Impact factor: 4.534

8.  JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

Authors:  Kian Kani; Carolina Garri; Katrin Tiemann; Paymaneh D Malihi; Vasu Punj; Anthony L Nguyen; Janet Lee; Lindsey D Hughes; Ruth M Alvarez; Damien M Wood; Ah Young Joo; Jonathan E Katz; David B Agus; Parag Mallick
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

9.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

10.  c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.

Authors:  X Xie; T S Kaoud; R Edupuganti; T Zhang; T Kogawa; Y Zhao; G B Chauhan; D N Giannoukos; Y Qi; D Tripathy; J Wang; N S Gray; K N Dalby; C Bartholomeusz; N T Ueno
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.